Latest Insider Transactions at Neurocrine Biosciences Inc (NBIX)
This section provides a real-time view of insider transactions for Neurocrine Biosciences Inc (NBIX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NEUROCRINE BIOSCIENCES INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NEUROCRINE BIOSCIENCES INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 28
2024
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
75,000
-45.83%
|
$10,050,000
$134.69 P/Share
|
|
Feb 28
2024
|
Eric Benevich Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
75,000
+31.05%
|
$4,575,000
$61.13 P/Share
|
|
Feb 27
2024
|
Leslie V Norwalk Director |
SELL
Open market or private sale
|
Direct |
8,000
-100.0%
|
$1,080,000
$135.67 P/Share
|
|
Feb 27
2024
|
Leslie V Norwalk Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+50.0%
|
$672,000
$84.95 P/Share
|
|
Feb 20
2024
|
Richard F Pops Director |
SELL
Open market or private sale
|
Direct |
15,000
-33.7%
|
$1,980,000
$132.47 P/Share
|
|
Feb 20
2024
|
Richard F Pops Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+25.21%
|
$180,000
$12.98 P/Share
|
|
Feb 13
2024
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,114
-4.49%
|
$147,048
$132.96 P/Share
|
|
Feb 13
2024
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,098
-2.69%
|
$144,936
$132.99 P/Share
|
|
Feb 13
2024
|
Jude Onyia Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,432
-9.84%
|
$189,024
$132.94 P/Share
|
|
Feb 13
2024
|
Kyle Gano Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,352
-0.99%
|
$178,464
$132.89 P/Share
|
|
Feb 13
2024
|
Kevin Charles Gorman Director |
SELL
Open market or private sale
|
Direct |
2,832
-0.55%
|
$376,656
$133.02 P/Share
|
|
Feb 13
2024
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
796
-4.24%
|
$105,868
$133.04 P/Share
|
|
Feb 13
2024
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
716
-8.71%
|
$95,228
$133.03 P/Share
|
|
Feb 13
2024
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,098
-2.63%
|
$146,034
$133.01 P/Share
|
|
Feb 13
2024
|
David W. Boyer Chief Corp. Affairs Officer |
SELL
Open market or private sale
|
Direct |
1,811
-14.56%
|
$240,863
$133.08 P/Share
|
|
Feb 13
2024
|
Matt Abernethy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,352
-4.11%
|
$178,464
$132.85 P/Share
|
|
Feb 13
2024
|
Kevin Charles Gorman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,090
+0.5%
|
$198,510
$39.62 P/Share
|
|
Feb 08
2024
|
David W. Boyer Chief Corp. Affairs Officer |
SELL
Open market or private sale
|
Direct |
1,328
-11.31%
|
$179,280
$135.49 P/Share
|
|
Feb 08
2024
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
1,329
-3.64%
|
$179,415
$135.5 P/Share
|
|
Feb 08
2024
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
911
-2.3%
|
$122,074
$134.24 P/Share
|
|
Feb 08
2024
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
980
-4.14%
|
$131,320
$134.21 P/Share
|
|
Feb 08
2024
|
Kevin Charles Gorman Director |
SELL
Open market or private sale
|
Direct |
2,274
-0.45%
|
$304,716
$134.15 P/Share
|
|
Feb 08
2024
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
980
-2.41%
|
$131,320
$134.19 P/Share
|
|
Feb 08
2024
|
Kyle Gano Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
980
-0.73%
|
$131,320
$134.2 P/Share
|
|
Feb 08
2024
|
Matt Abernethy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
980
-3.13%
|
$131,320
$134.21 P/Share
|
|
Feb 06
2024
|
David W. Boyer Chief Corp. Affairs Officer |
SELL
Open market or private sale
|
Direct |
456
-4.36%
|
$64,296
$141.96 P/Share
|
|
Feb 06
2024
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
1,215
-3.34%
|
$172,530
$142.07 P/Share
|
|
Feb 06
2024
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,041
-2.67%
|
$147,822
$142.17 P/Share
|
|
Feb 06
2024
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,121
-4.88%
|
$159,182
$142.24 P/Share
|
|
Feb 06
2024
|
Kevin Charles Gorman Director |
SELL
Open market or private sale
|
Direct |
3,040
-0.6%
|
$431,680
$142.18 P/Share
|
|
Feb 06
2024
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,280
-3.2%
|
$181,760
$142.12 P/Share
|
|
Feb 06
2024
|
Kyle Gano Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,600
-1.19%
|
$227,200
$142.2 P/Share
|
|
Feb 06
2024
|
Matt Abernethy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,280
-4.17%
|
$181,760
$142.19 P/Share
|
|
Feb 01
2024
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
623
-8.32%
|
$86,597
$139.77 P/Share
|
|
Jan 31
2024
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,250
-3.27%
|
$175,000
$140.65 P/Share
|
|
Jan 31
2024
|
Jude Onyia Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
126
-1.05%
|
$17,766
$141.94 P/Share
|
|
Jan 31
2024
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,457
-6.54%
|
$203,980
$140.79 P/Share
|
|
Jan 31
2024
|
Kevin Charles Gorman Director |
SELL
Open market or private sale
|
Direct |
2,707
-0.54%
|
$378,980
$140.69 P/Share
|
|
Jan 31
2024
|
Kyle Gano Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,541
-1.16%
|
$215,740
$140.7 P/Share
|
|
Jan 31
2024
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
1,740
-4.69%
|
$245,340
$141.32 P/Share
|
|
Jan 31
2024
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
422
-6.27%
|
$59,502
$141.94 P/Share
|
|
Jan 31
2024
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,207
-3.11%
|
$168,980
$140.78 P/Share
|
|
Jan 31
2024
|
David W. Boyer Chief Corp. Affairs Officer |
SELL
Open market or private sale
|
Direct |
2,096
-16.32%
|
$293,440
$140.79 P/Share
|
|
Jan 31
2024
|
Matt Abernethy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,283
-4.34%
|
$179,620
$140.72 P/Share
|
|
Jan 22
2024
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
10,000
-21.8%
|
$1,390,000
$139.86 P/Share
|
|
Jan 22
2024
|
Darin Lippoldt Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+17.89%
|
$790,000
$79.02 P/Share
|
|
Jan 09
2024
|
Kevin Charles Gorman Director |
SELL
Open market or private sale
|
Direct |
62,023
-11.04%
|
$8,311,082
$134.01 P/Share
|
|
Jan 09
2024
|
Kevin Charles Gorman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
62,023
+9.94%
|
$1,178,437
$19.59 P/Share
|
|
Jan 08
2024
|
Kevin Charles Gorman Director |
SELL
Open market or private sale
|
Direct |
105,835
-17.48%
|
$13,970,220
$132.44 P/Share
|
|
Jan 08
2024
|
Kevin Charles Gorman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
105,835
+14.88%
|
$2,010,865
$19.59 P/Share
|